Background/Aim: Evasion from cell death occurs in prostate cancer (PCa). We verified
whether serum levels of cell death markers can have diagnostic value in PCa. Patients and …

Introduction: Immunogenic cell death markers are released from apoptotic and necrotic cells
upon pathologic or therapeutic causes and stimulate the innate and adaptive immune …

Receptor for advanced glycation end products (RAGE), along with its ligand high mobility
group box 1 (HMGB1), is believed to play an important role in prostate cancer. The aim of …

As a DNA-binding protein, high mobility group box 1 (HMGB1) has been shown be involved
in various biological activities, including transcription regulation, DNA repair, genomic …

Serum biomarkers are urgently needed for patient stratification and efficient treatment
monitoring in pancreatic cancer (PC). Within a prospective diagnostic observation study …

Simple Summary Ovarian cancer is often diagnosed only in advanced stages, which limits
therapeutic options and prognosis. Therefore, better and easily accessible methods for the …

Prostate cancer (PCa) is the second most common cancer in men. The indolent course of
the disease makes the treatment choice a challenge for physicians and patients. In this …

Background A majority of prostate cancer cells are in a non-proliferating, G0 (quiescent)
phase of the cell cycle and may lie dormant for years before activation into a proliferative …

Background The clinical course of prostate cancer (PCa) measured by biochemical failure
(BF) after prostatectomy remains unpredictable in many patients, particularly in intermediate …

METHODS After transient transfection of PC3 and DU-145 cells with HMGB1 siRNA, diverse
experiments were performed to evaluate the changes in proliferation, apoptosis, migration …